ATE103328T1 - Fuer ein glykoprotein des aids-virus kodierende virus-vektoren, vakzin und antikoerper. - Google Patents

Fuer ein glykoprotein des aids-virus kodierende virus-vektoren, vakzin und antikoerper.

Info

Publication number
ATE103328T1
ATE103328T1 AT87400790T AT87400790T ATE103328T1 AT E103328 T1 ATE103328 T1 AT E103328T1 AT 87400790 T AT87400790 T AT 87400790T AT 87400790 T AT87400790 T AT 87400790T AT E103328 T1 ATE103328 T1 AT E103328T1
Authority
AT
Austria
Prior art keywords
virus
glycoprotein
vaccine
aids
antibodies encoding
Prior art date
Application number
AT87400790T
Other languages
English (en)
Inventor
Marie-Paule Kieny
Guy Rautmann
Jean-Pierre Lecocq
Hobson Simon Wain
Marc Girard
Luc Montagnier
Original Assignee
Transgene Sa
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26225146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE103328(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8605043A external-priority patent/FR2596771B1/fr
Application filed by Transgene Sa, Pasteur Institut filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE103328T1 publication Critical patent/ATE103328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT87400790T 1986-04-08 1987-04-08 Fuer ein glykoprotein des aids-virus kodierende virus-vektoren, vakzin und antikoerper. ATE103328T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8605043A FR2596771B1 (fr) 1986-04-08 1986-04-08 Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
FR8615106A FR2606029B2 (fr) 1986-04-08 1986-10-29 Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
EP87400790A EP0245136B1 (de) 1986-04-08 1987-04-08 Für ein Glykoprotein des AIDS-Virus kodierende Virus-Vektoren, Vakzin und Antikörper

Publications (1)

Publication Number Publication Date
ATE103328T1 true ATE103328T1 (de) 1994-04-15

Family

ID=26225146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87400790T ATE103328T1 (de) 1986-04-08 1987-04-08 Fuer ein glykoprotein des aids-virus kodierende virus-vektoren, vakzin und antikoerper.

Country Status (12)

Country Link
EP (1) EP0245136B1 (de)
JP (3) JP2719917B2 (de)
KR (1) KR960001819B1 (de)
AT (1) ATE103328T1 (de)
AU (1) AU604696B2 (de)
CA (1) CA1341353C (de)
DE (1) DE3789400T2 (de)
DK (1) DK175613B1 (de)
ES (1) ES2052589T3 (de)
FR (1) FR2606029B2 (de)
PT (1) PT84640B (de)
WO (1) WO1987006260A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
CA2011299A1 (en) * 1989-03-03 1990-09-03 Franklin Volvovitz Aids therapy
JP3203599B2 (ja) * 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6228608B1 (en) * 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
GB9215233D0 (en) * 1992-07-17 1992-09-02 Pitman Moore Inc Vaccines
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
CN1304580C (zh) * 2004-07-09 2007-03-14 楼伟 重组表达人获得性免疫缺陷病毒I型的表面糖蛋白gp160
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
EP0243029A1 (de) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Rekombinantes Vaccinia-Virus, das ein menschliches Retrovirus-Gen ausdrückt

Also Published As

Publication number Publication date
CA1341353C (fr) 2002-04-02
ES2052589T3 (es) 1994-07-16
DK175613B1 (da) 2004-12-27
EP0245136A1 (de) 1987-11-11
DK641787A (da) 1987-12-07
WO1987006260A1 (fr) 1987-10-22
JPH1059868A (ja) 1998-03-03
JPH01500161A (ja) 1989-01-26
DK641787D0 (da) 1987-12-07
FR2606029B2 (fr) 1989-02-03
PT84640B (pt) 1989-11-30
JPH08224090A (ja) 1996-09-03
AU604696B2 (en) 1991-01-03
JP2719917B2 (ja) 1998-02-25
KR960001819B1 (en) 1996-02-05
EP0245136B1 (de) 1994-03-23
FR2606029A2 (fr) 1988-05-06
DE3789400D1 (de) 1994-04-28
JP2743164B2 (ja) 1998-04-22
PT84640A (fr) 1987-05-01
KR880701283A (ko) 1988-07-26
DE3789400T2 (de) 1994-09-01
AU7234987A (en) 1987-11-09

Similar Documents

Publication Publication Date Title
ATE103328T1 (de) Fuer ein glykoprotein des aids-virus kodierende virus-vektoren, vakzin und antikoerper.
CY1113731T1 (el) Μεθοδοι για δημιουργια παρασκευασματων κομιστων ανασυνδυασμενου aav υψηλου τιτλου απαλλαγμενων απο βοηθητικο ιο
ZA8997B (en) Recombinant vaccinia virus mva
CA2243570A1 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv
CZ63995A3 (en) Virus vectors and their use in gene therapy
DK33190D0 (da) Hiv-3 retrovirus og anvendelse heraf
ATE241014T2 (de) Hiv-2 varianten
EP0429477A4 (en) Synthetic vaccine against aids virus
ZA853081B (en) Vaccine against rabies and process for preparation thereof
FI885296A0 (fi) Rekombinant hiv-2 polypeptid.
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
DK498387D0 (da) Virus-dna-sekvens
DK76688D0 (da) Vaccine indeholdende f-proteinet fra aids-virus
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.
ES2054841T3 (es) Vector viral y adn recombinante que codifica para una o unas proteinas de estructura (ha, f y/o np), de un morbilivirus.
TH33841A (th) รีคอมบิแนนท์เอวิพอคซ์ไวรัส การเพาะเลี้ยงเซลล์ที่ติดเชื้อไวรัสนี้ และวัคซีนสำหรับสัตว์ปีกที่อนุพัทธ์จากไวรัสนี้

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time